The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...
Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.
Kura Oncology (KURA) and Kyowa Kirin provided encouraging clinical data from KOMET-007, a Phase 1 dose-escalation trial of ziftomenib, a highly ...
Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed ...
The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...
No Treatment Emergent Adverse Events Leading to Dose Reduction In Non-Hodgkin’s Lymphoma, Cemsidomide Monoth Much of the East Coast was in for a polar reprieve. But that warm-up comes with a price: ...
Palantir Technologies Inc. today announced an expansion of its contract with the U.S. Special Operations Command (USSOCOM) to deliver technology solutions in support of enterprise capabilities. The ...
A subgroup analysis showed that epcoritamab is effective regardless of CAR T–exposure in patients with R/R LBCL.
Verition Fund Management LLC acquired a new position in shares of Nuvalent, Inc. (NASDAQ:NUVL – Free Report) during the 3rd ...
An investigational therapy for post-traumatic stress disorder (PTSD) improved symptom severity as soon as one month into a 12 ...
Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's ...
Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 – – 100% of 1L NPM1-m and 96% of 1L KMT2A-r AML patients alive ...